Translational Development Acquisition Corp.
TDAC
$10.33
$0.010.10%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 763.20K | 543.80K | 197.20K | 547.60K | 486.80K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 763.20K | 543.80K | 197.20K | 547.60K | 486.80K |
Operating Income | -763.20K | -543.80K | -197.20K | -547.60K | -486.80K |
Income Before Tax | 3.04M | 1.41M | -71.80K | -547.60K | -486.80K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 3.04 | 1.41 | -0.07 | -0.55 | -0.49 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 3.04M | 1.41M | -71.80K | -547.60K | -486.80K |
EBIT | -763.20K | -543.80K | -197.20K | -547.60K | -486.80K |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | 0.13 | 0.05 | -0.02 | -0.14 | -0.12 |
Normalized Basic EPS | 0.08 | 0.03 | -0.01 | -0.08 | -0.08 |
EPS Diluted | 0.13 | 0.05 | -0.02 | -0.14 | -0.12 |
Normalized Diluted EPS | 0.08 | 0.03 | -0.01 | -0.08 | -0.08 |
Average Basic Shares Outstanding | 53.28M | 35.43M | 17.57M | 16.20M | 16.20M |
Average Diluted Shares Outstanding | 53.28M | 35.43M | 17.57M | 16.20M | 16.20M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |